Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon beta-1b - Nuron Biotech

Drug Profile

Interferon beta-1b - Nuron Biotech

Alternative Names: BaroFeron; Interferon beta-1b - Nuron Biotech/BaroFold; NU-100; Recombinant human interferon beta - BaroFold/Nuron Biotech; Relonsiv

Latest Information Update: 30 Apr 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BaroFold
  • Developer Nuron Biotech
  • Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
  • Mechanism of Action Immunomodulators; Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 13 Nov 2012 Nuron Biotech completes enrolment in its phase III trial for Multiple sclerosis in Italy, Bulgaria, Hungary, Poland, Spain, Belarus, Croatia, Georgia, Serbia, Ukraine, Russia & Lebanon (NCT01464905)
  • 31 Oct 2011 Phase-III clinical trials in Multiple sclerosis in Bulgaria (SC)
  • 31 Oct 2011 Phase-III clinical trials in Multiple sclerosis in Croatia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top